Kinetics of molecular response. The proportion of patients in MMolR was 3%, 20%, 52%, 66%, 73%, and 85%, at 1, 2, 3, 6, 9, and 12 months. The median BCR-ABL transcript level was 4.704, 0.456, 0.063, 0.018, 0.018, and 0.006, at 1, 2, 3, 6, 9, and 12 months.